How Pharmaceutical Incumbents Stifle Innovation and Inhibit Disruptors

Alex, Nick, and guest speaker D.A. Wallach discuss some of the disreputable ways incumbents in the pharmaceutical industry stifle innovation and inhibit disruptors. They go over methods including cutting off data flows and wielding the leverage of negotiated pricing across large portfolios.

Life Sciences Investor D.A. Wallach Interview:

Filed under: Winner Take All | Topics:

Weekly Industry Newsletter

Enterprise Hacks

Enterprise Hacks brings the community of corporate innovators together to beat big tech at its own game.

Read, Post, Engage

Top Posts

  • B2B Chemical Marketplaces and Tech Startups: Landscape and State of the Industry

    Read more

  • Platform vs. Linear: Business Models 101

    Read more

  • Amazon Business – 2020 Report

    Read more

  • Platform Business Model – Definition | What is it? | Explanation

    Read more

  • The Value of Digital Transformation: How Investors Evaluate “Tech”

    Read more